Antitumor activity of asukamycin, a secondary metabolite from the actinomycete bacterium Streptomyces nodosus subspecies asukaensis

International Journal of Molecular Medicine

Volumn 24, Issue 5, 2009, Pages 711-715

  Shipley, Paul R ^a   Donnelly, Caitlin C A ^a   Le, Cuong H ^a   Bernauer, Ashley D ^a   Klegeris, Andis ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antitumor agents; Astrocytomas; Asukamycin; Cancer; Leukemia; Manumycin metabolites

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ASUKAMYCIN; CASPASE 3; CASPASE 8; MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA CELL; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; METABOLITE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOMYCES; STREPTOMYCES ASUKAENSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CASPASE 3; CASPASE 8; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; POLYENES; POLYUNSATURATED ALKAMIDES; STREPTOMYCES;

EID: 70350778326     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000283     Document Type: Article

References (28)

1. Sattler I, Thiericke R and Zeeck A: The manumycin-group metabolites. Nat Prod Rep 15: 221-240, 1998.
2. Sugita M, Sugita H and Kaneki M: Farnesyltransferase inhibitor, manumycin A, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. Aterioscler Thromb Vasc Biol 27: 1390-1395, 2007.
3. Bernier M, Kwon YK, Pandey SK, et al: Binding of manumycin A inhibits IκB kinase ß activity. J Biol Chem 281: 2551-2561, 2006.
4. Kohno J, Nishio M, Kawano K, et al: TMC-1 A, B, C and D, new antibiotics of the manumycin group produced by Streptomyces sp. Taxonomy, production, isolation, physico-chemical properties, structure elucidation and biological properties. J Antibiot 46: 1212-1220, 1996.
5. Zeeck A, Schröder K, Frobel K, Grote R and Thiericke R: The structure of manumycin. I. Characterization, structure elucidation and biological activity. J Antibiot 40: 1530-1540, 1987.
6. She M, Pan J, Sun L and Yeung SC: Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells. Leukemia 19: 595-602, 2005.
7. She M, Yang H, Sun L and Yeung SC: Redox control of manumycin A-induced apoptosis in anaplastic thyroid cancer cells: involvement of the xenobiotic apoptotic pathway. Cancer Biol Ther 5: 275-280, 2006.
8. Shu YZ, Huang S, Wang RR, et al: Manumycins E, F and G, new members of manumycin class antibiotics from Streptomyces sp. J Antibiot 47: 324-333, 1994.
9. Di Paolo A, Danesi R, Nardini D, et al: Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br J Cancer 82: 905-912, 2000.
10. Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM and Liu ZC: Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. Int J Mol Med 12: 955-959, 2003.
11. Omura S, Kitao C, Tanaka H, Oiwa R and Takahashi Y: A new antibiotic, asukamycin, produced by Streptomyces. J Antibiot 29: 876-881, 1976.
12. Hu YD and Floss HG: Further studies on the biosynthesis of the manumycin-type antibiotic, asukamycin, and the chemical synthesis of protoasukamycin. J Am Chem Soc 126: 3837-3844, 2004.
13. Cho H, Sattler I, Beale JM, Zeeck A and Floss HG: Some aspects of the stereochemistry and biosynthesis of asukamycin. J Org Chem 58: 7925-7928, 1993.
14. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
15. Klegeris A and McGeer PL: Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity. Glia 51: 56-64, 2005.
16. Gurtu V, Kain SR and Zhang G: Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal Biochem 251: 98-102, 1997.
17. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dyebinding. Anal Biochem 72: 248-254, 1976.
18. Thiericke R, Zeeck A, Nakagawa A, et al: Biosynthesis of the manumycin group antibiotics. J Am Chem Soc 112: 3979-3987, 1990.
19. Hara M, Akasaka K, Akinaga S, et al: Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90: 2281-2285, 1993.
20. Mazieres J, Pradines A and Favre G: Perspectives on farnesyl-transferase inhibitors in cancer therapy. Cancer Lett 206: 159-167, 2004.
21. Sears KT, Daino H and Carey GB: Reactive oxygen species-dependent destruction of MEK and Akt in manumycin stimulated death of lymphoid tumor and myeloma cell lines. Int J Cancer 122: 1496-1505, 2008.
22. Pan J, Xu G and Yeung SC: Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 86: 4731-4740, 2001.
23. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
24. Chiacchiera F and Simone C: Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38α in colorectal tumors. Cancer Lett 265: 16-26, 2008.
25. Park SJ and Kim IS: The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 146: 506-513, 2005.
26. Frassanito MA, Mastromauro L, Cusmai A and Dammacco F: Blockade of the Ras pathway by manumycin, a farnesyl-transferase inhibitor, overcomes the resistance of myeloma plasma cells to Fas-induced apoptosis. Clin Exp Med 4: 174-182, 2005.
27. Ferrari D, Stepczynska A, Los M, Wesselborg S and Schulze-Osthoff K: Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J Exp Med 188: 979-984, 1998.
28. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.